期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

含奥沙利铂化疗方案治疗晚期原发性肝细胞癌的研究进展 被引量：1

Research progress of oxaliplatin-based regimen for advanced hepatocellular carcinoma
原文传递
导出
摘要 索拉非尼是目前唯一被多国批准的治疗晚期原发性肝细胞癌（HCC）的分子靶向药物，但其对生存期改善有限，最终出现病情进展。近几年，含奥沙利铂的化疗方案显示出良好的临床疗效，且患者耐受性可，为晚期 HCC 患者提供了新的治疗选择。 Sorafenib is currently the only systematic molecular targeted drug approved by many coun-tries for the treatment of advanced HCC.But sorafenib limites has survival improvement,patients appear inevi-table disease progression soon.In recent years,Oxaliplatin-based regimens showed promising anti-tumor activi-ty,safety and low toxicities,which provides a new way for treatment of advanced HCC.
作者 宋迪迪 刘传勇
机构地区 泰山医学院研究生部 山东大学附属济南市中心医院肿瘤科
出处 《国际肿瘤学杂志》 CAS 2016年第7期545-547,共3页 Journal of International Oncology
关键词 癌 肝细胞 药物疗法 奥沙利铂 Carcinoma,hepatocellular Drug therapy Oxaliplatin
分类号 R735.7 [医药卫生—肿瘤]
  • 相关文献

参考文献15

  • 1Jemal A, Bray F, Center MM, et al. Global cancer statistics[J]. CA Cancer J Clin, 2011,61 (2) : 69-90.
  • 2Cheng AL, Kang YK, Chen Z, et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatoeeilular car- cinoma: a phase ]~ randomised, double-blind, placebo-controlled trl- M[J]. Lancet Oncol, 2009, 10(1) : 25-34.
  • 3Lv Y, Liang R, Hu X, et al. Combination of oxaliplatin and S-I ver- sus sarafenib alone in patients with advanced hepatocellular carcinoma [J]. Pharmazie, 2014, 69(10): 759-763..
  • 4Petrelli F, Coinu A, Borgonovo K, et al. Oxaliplatin-based chemo- therapy: a new option in advanced hepatocenular carcinoma. A sys- tematic review and pooled analysis[ J]. Clin Oncol (R Coil Radiol), 2014, 26(8) : 488-496.
  • 5Dhooge M, Coriat R, Mir O, et al. Feasibility of gemcitabine plus oxaliplatin in advanced hepatocellular carcinoma patients with Child- Pugh B cirrhosis[ J~. Ontology, 2013, 84 ( 1 ) : 32-38.
  • 6Qin SK, Bai YX, Lira HY, et al. Randomized, muhicenter, open-la- bel study of oxaliplatin plus fluorouracil/leucov versus doxombiein as palliative chemotherapy in patients with advanced hepatocellular carcinoma from Asia[ J]. J Clin Oncol, 2013, 31 (28) : 3501-3508.
  • 7Zaanan A, Williet N, Hebbar M, et al. Gemcitabine plus oxaliplatin in advanced hepatocellular carcinoma: a large multicenter AGEO study[J]. J Hepatol, 2013, 58(1) : 81-88.
  • 8Louafi S, Boige V, Ducreux M, et al. Gemcitabine plus oxaliplatin (GEMOX) in patients with advanced hepatocellular carcinoma (HCC) : results of a phase II study[J]. Cancer, 2007, 109(7) : 1384-1390.
  • 9Mir O, Coriat R, Boudou-Rouquette P, et al. Gemcitabine and oxali- platin as second-line treatment in patients with hepatocelltdar carcino- ma pre-treated with sorafenib[J]. Med Oncol, 2012, 29(4) : 2793- 2799.
  • 10Patrikidou A, Sinapi I, Regnault H, et al. Gemcitabine and oxali- platin chemotherapy for advanced hepatocellular carcinoma after fai- lure of anti-angiogenic therapies[J]. Invest New Drugs, 2014, 32 (5) : 1028-1035.

二级参考文献16

  • 1秦叔逵,曹梦苒,钱军,华海清,王琳,何泽明.奥沙利铂为主的FOLFOX方案治疗晚期原发性肝癌[J].临床肿瘤学杂志,2005,10(1):58-60. 被引量：77
  • 2Jemal A, Bray F, Center MM, et al. Global cancer statistics[J] . CA CancerJ Clin,2011 ,61 (2) :69-90.
  • 3Yen Y , Lim OW, Chung V, et al. Phase II study of oxaliplatin in patients with unresectable, metastatic, or recurrent hepatocellular cancer: a California Cancer Consortium Trial[J] . AmJ Clin Oncol,2008,31 (4) :317-322.
  • 4Qin S,Bai Y,Lim HY,et al. Randomized, multicenter, open-label study of oxaliplatin plus fluorouraciVleucovorin versus doxorubicin as palliative chemotherapy in patients with advanced hepatocellular carcinoma from Asia[J].J Clin Oncol, 2013 , 31 (28) :3501-3508.
  • 5IlovetJ , Ricci S, Mazzaferro V, et al. Sorafenib in advanced hepatocellular carcinomaJ J'j.N Eng!J Med,2008,359(4) :378-390.
  • 6Cheng AL, Kang YK, Chen Z, et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase ill randomised, double-blind, placebo-controlled trial[J] . Lancet Oncol ,2009,10(1) :25-34.
  • 7Qin SK, Wang YJ , Wu Q, et al. Preliminary results of a phase II trial of FOLFOX 4 regimen in Chinese patients with unresectable primary liver cancer[J].J Clin Oncol, 2006, 24 ( 18 Suppl ) : 14065.
  • 8Boige V, RaoulJL, PignonJ, et al. Multicentre phase II trial of capecitabine plus oxaliplatin ( XELOX) in patients with advanced hepatocellular carcinoma: FFCO 03-03 trial[J] . BrJ Cancer, 2007,97(7) :862-867.
  • 9Worns MA, Weinmann A, Pfingst K, et al. Safety and efficacy of sorafenib in patients with advanced hepatocellular carcinoma in consideration of concomitant stage of liver cirrhosis[J] .J Clin Gastroenterol ,2009 ,43( 5) :489-495.
  • 10Yau TC, Cheung FY, Lee F, et al. A multicenter phase II study of sorafenib, capecitabine, and oxaliplatin ( SECOX) in patients with advanced hepatocellular carcinoma: final results of Hong Kong-Singapore Hepatocellular Carcinoma Research Collaborative Group study[J].J Clin Oncol,2013,31 (suppl) :a4117.

共引文献28

同被引文献25

引证文献1

二级引证文献18

国际肿瘤学杂志
2016年 第7期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部